Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 2/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 2/20 | 0.33 |
| ▸ | F3 | P13726 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29265855 | 0.90 | AAK1 (0.39) | BTKSRCFGFR4EGFRJAK3 | |
| SCHEMBL29265892 | 0.89 | SRC (0.38) | BTKSRCFGFR1FGFR3NAMPT | |
| SCHEMBL29265834 | 0.87 | SRC (0.36) | BTKSRCFGFR1FGFR2FGFR4 | |
| SCHEMBL29265807 | 0.81 | ABL1 (0.39) | BTKSRCEGFRKDRJAK3 | |
| SCHEMBL30325694 | 0.80 | BTK (0.45) | BTKEGFRKCNH2 | |
| SCHEMBL30325933 | 0.79 | KDR (0.37) | SRCFGFR1FGFR3NAMPTF2 | |
| SCHEMBL30325818 | 0.79 | BTK (0.40) | BTKEGFRKCNH2 | |
| SCHEMBL30325733 | 0.78 | BRD4 (0.38) | BTKFGFR4AXLMERTKEGFR | |
| SCHEMBL30325883 | 0.78 | KDR (0.37) | SRCFGFR1FGFR3NAMPTF2 | |
| SCHEMBL29265793 | 0.78 | TP53 (0.40) | BTKSRCFGFR1EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | claimed |
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | claimed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | claimed |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | BTK 168/4885SRC 37/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.